Multivitamins and phospholipids complex protects the hepatic cells from androgenic-anabolic-steroids-induced toxicity

Clinical Toxicology

Volumn 46, Issue 1, 2008, Pages 57-66

  Pagonis, Thomas A ^a,c   Koukoulis, George N ^a   Hadjichristodoulou, Christos S ^a   Toli, Paraskevi N ^a   Angelopoulos, Nikiforos V ^b  

^a University of Thessaly School of Medicine   (Greece)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^c NONE   (Greece)

Author keywords

Anabolic steroids toxicity; Hepatoprotection; Steroid induced liver damage

Indexed keywords

ANABOLIC AGENT; ANDROGEN; CHLORODEHYDROMET HYLTESTOSTERONE; COMPOUND N; CREATINE KINASE; ETHYLESTRENOL; FLUOXYMESTERONE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; MESTEROLONE; METANDIENONE; METENOLONE ACETATE; METHANDRIOL; METHYLTESTOSTERONE; MULTIVITAMIN; NANDROLONE CYPIONATE; NANDROLONE DECANOATE; NANDROLONE HEXYLOPHENYLPROPIONATE; NANDROLONE PHENPROPIONATE; NANDROLONE UNDECANOATE; NORETHANDROLONE; OXANDROLONE; OXYMETHOLONE; PHOSPHOLIPID; QUINBOLONE; STANOZOLOL; STEROID; TESTOSTERONE DERIVATIVE; TESTOSTERONE UNDECANOATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BLOOD LEVEL; CELL PROTECTION; CONTROLLED STUDY; DRUG ABUSE; DRUG DETOXIFICATION; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER CELL; LIVER PROTECTION; LIVER TOXICITY; MALE; METHODOLOGY; NORMAL HUMAN; OBSERVATIONAL STUDY;

ADULT; ANABOLIC AGENTS; COHORT STUDIES; DOPING IN SPORTS; DRUG COMBINATIONS; FEMALE; HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PHOSPHOLIPIDS; SPORTS; SUBSTANCE-RELATED DISORDERS; VITAMINS;

EID: 37649014172     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650701590910     Document Type: Article

References (71)

1. Mottram DR, George AJ. Anabolic steroids. Baillieres Best Pract Res Clin Endocrinol Metab Mar 2000; 14(1):55-69.
2. Kuhn CM. Anabolic steroids. Recent Prog Horm Res 2002; 57:411-34.
3. Jamin C. The concept of selective action steroids. Gynecol Obstet Fertil 2000; 28(12):931-9.
4. Mooradian AD, Morely JE, Korenman SG. Biological actions of androgens. Endocrine Reviews 1987; 8:1-28.
5. Yesalis CE, Bahrke MS. Anabolic-androgenic steroids and related substances. Curr Sports Med Rep 2002; 1(4):246-52.
6. Kutscher EC, Lund BC, Perry PJ. Anabolic steroids: A review for the clinician. Sports Med 2002; 32(5):285-96.
7. Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther 2001; 23(9):1355-90.
8. Kicman AT, Gower DB. Anabolic steroids in sport: biochemical, clinical and analytical perspectives. Ann Clin Biochem 2003; 40(Pt. 4):321-56.
9. Pavlatos AM, Fultz O, Monberg MJ, et al. Review of oxymetholone: A 17alpha-alkylated anabolic-androgenic steroid. Clin Ther 2001; 23(6):789-801.
10. Evans NA. Current concepts in anabolic-androgenic steroids. Am J Sports Med 2004; 32(2):534-42.
11. O'Sullivan AJ, Kennedy MC, Casey JH, et al. Anabolic-androgenic steroids: Medical assessment of present, past and potential users. Med J Aust 2000; 173(6):323-7.
12. Griggs RC, Kingston W, Jozefowicz RF, Herr BF, Forbes G, Halliday D. Effects of testosterone on muscle mass and protein synthesis. J Appl Physiol 1989; 66:498-503.
13. Tamaki T, Uchiyama S, Uchiyama Y, et al. Anabolic steroids increase exercise tolerance. Am J Physiol Endocrinol Metab 2001; 280(6):E973-81.
14. Rogol AD. Sex steroid and growth hormone supplementation to enhance performance in adolescent athletes. Curr Opin Pediatr 2000; 12(4):382-7.
15. Inigo MA, Arrimadas E, Arroyo D. 43 cycles of anabolic steroid treatment studied in athletes: The uses and secondary effects. Rev Clin Esp 2000; 200(3):133-8.
16. Perry PJ, Andersen KH, Yates WR. Illicit anabolic steroid use in athletes: A case series analysis. Am J Sports Med 1990;18:422-428.
17. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004; 34(8):513-54.
18. Feller AA, Mylonakis E, Rich JD. Medical complications of anabolic steroids. Med Health R I 2002; 85(11):338-40.
19. Stimac D, Milic S, Dintinjana RD, et al. Androgenic/Anabolic steroid-induced toxic hepatitis. J Clin Gastroenterol 2002; 35(4):350-2.
20. Segal S, Cooper J, Bolognia J. Treatment of lipodermatosclerosis with oxandrolone in a patient with stanozolol-induced hepatotoxicity. J Am Acad Dermatol 2000; 43(3):558-9.
21. Teschke R. Drug-induced liver diseases. Z Gastroenterol 2002; 40(5):305-26.
22. Nakao A, Sakagami K, Nakata Y, et al. Multiple hepatic adenomas caused by long-term administration of androgenic steroids for aplastic anemia in association with familial adenomatous polyposis. J Gastroenterol 2000; 35(7):557-62.
23. Bolding G, Sherr L, Elford J. Use of anabolic steroids and associated health risks among gay men attending London gyms. Addiction 2002; 97(2):195-203.
24. Pertusi R, Dickerman RD, McConathy WJ. Evaluation of aminotransferase elevations in a bodybuilder using anabolic steroids: Hepatitis or rhabdomyolysis? J Am Osteopath Assoc 2001; 101(7):391-4.
25. Thomas S, Wolf SE, Murphy KD, et al. The long-term effect of oxandrolone on hepatic acute phase proteins in severely burned children. J Trauma 2004; 56(1):37-44.
26. Urhausen A, Torsten A, Wilfried K. Reversibility of the effects on blood cells, lipids, liver function and hormones in former anabolic-androgenic steroid abusers. J Steroid Biochem Mol Biol 2003; 84(2-3):369-75.
27. Fudala PJ, Weinrieb RM, Calarco JS, et al. An evaluation of anabolic-androgenic steroid abusers over a period of 1 year: Seven case studies. Ann Clin Psychiatry 2003; 15(2):121-30.
28. Green GA, Uryasz FD, Petr TA, et al. NCAA study of substance use and abuse habits of college student-athletes. Clin J Sport Med 2001; 11(1):51-6.
29. Laure P. Doping: Epidemiological studies. Presse Med 2000; 29(24):1365-72.
30. Millman RB, Ross EJ. Steroid and nutritional supplement use in professional athletes. Am J Addict 2003; 12 Suppl 2:S48-54.
31. Ishak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liver Dis 1987; 7:230-236.
32. Hickson RC, Ball KL, Falduto MT. Adverse effects of anabolic steroids. Med Toxicol Adverse Drug Exp 1989; 4:254-271.
33. de Silva HA, Saparamadu PA, Thabrew MI, et al. Liv.52 in alcoholic liver disease: A prospective, controlled trial. J Ethnopharmacol 2003; 84(1):47-50.
34. Horejsova M, Urban J. The effect of polyene phosphatidylcholine (Essentiale forte) in the treatment of liver steatosis and ultrasound findings, a preliminary study. Cas Lek Cesk 1994; 133(12):366-9.
35. Lata J, Dastych M, Senkyrik M, et al. Protective effect of essential phospholipids on liver injury due to total parenteral nutrition. Vnitr Lek 2001; 47(9):599-603.
36. Prokopenko LG, Konoplia NA, Uteshev BS. Effect of essentiale and riboxin on immunosuppressive properties of thrombocytes and erythrocytes during liver intoxication. Eksp Klin Farmakol 2001; 64(4):37-41.
37. Shpagina LA, Bobrov SV. Administration of essential phospholipids in persons exposed to chemical industrial pollutants. Ter Arkh 2004; 76(2):63-6.
38. Inigo MA, Arrimadas E, Arroyo D. 43 cycles of anabolic steroid treatment studied in athletes: the uses and secondary effects. Rev Clin Esp 2000; 200(3):133-8.
39. Berning JM, Adams KJ, Stamford BA. Anabolic steroid usage in athletics: Facts, fiction, and public relations. J Strength Cond Res 2004; 18(4):908-17.
40. Gomez JE. Performance-enhancing substances in adolescent athletes. Tex Med 2002; 98(2):41-6.
41. Irving LM, Wall M, Neumark-Sztainer D, et al. Steroid use among adolescents: Findings from Project EAT. J Adolesc Health 2002; 30(4):243-52.
42. Wichstrom L, Pedersen W. Use of anabolic-androgenic steroids in adolescence: Winning, looking good or being bad? J Stud Alcohol 2001; 62(1):5-13.
43. Hartgens F, van Straaten H, Fideldij S, et al. Misuse of androgenic-anabolic steroids and human deltoid muscle fibers: Differences between polydrug regimens and single drug administration. Eur J Appl Physiol 2002; 86(3):233-9.
44. Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse. European Psychiatry, in press.
45. Paul GL. Dietary protein requirements of physically active individuals. Sports Med 1989; 8(3):154-176.
46. Jarvis M, McNaughton L, Seddon A, et al. The acute 1-week effects of the Zone diet on body composition, blood lipid levels, and performance in recreational endurance athletes. J Strength Cond Res 2002; 16(1):50-7.
47. Ziegler P, Nelson JA, Barratt-Fornell A, et al. Energy and macronutrient intakes of elite figure skaters. J Am Diet Assoc 2001; 101(3):319-25.
48. Peterson MD, Rhea MR, Alvar BA. Maximizing strength development in athletes: A meta-analysis to determine the dose-response relationship. J Strength Cond Res 2004; 18(2):377-82.
49. Marcos J, Pascual JA, de la Torre X, et al. Fast screening of anabolic steroids and other banned doping substances in human urine by gas chromatography/tandem mass spectrometry. J Mass Spectrom 2002; 37(10):1059-73.
50. Trout GJ, Kazlauskas R. Sports drug testing-an analyst's perspective. Chem Soc Rev 2004; 33(1):1-13.
51. Dickerman RD, Pertusi RM, Zachariah NY, Dufour DR, McConathy WJ. Anabolic steroid-induced hepatotoxicity: Is it overstated? Clin J Sport Med 1999; 9(1):34-9.
52. Boada LD, et al. Evaluation of acute and chronic hepatotoxic effects exerted by anabolic-androgenic steroid stanozolol in adult male rats. Archives of Toxicology 1999; 73:465-72.
53. Horejsova M, Urban J. The effect of polyene phosphatidylcholine (Essentiale forte) in the treatment of liver steatosis and ultrasound findings, a preliminary study. Cas Lek Cesk 1994; 133(12):366-9.
54. Mitra SK. Herbal products for liver diseases. Hepatology 2000; 31(2):546-7.
55. Dhiman RK. Herbal hepatoprotective agents: Marketing gimmick or potential therapies? Trop Gastroenterol 2003; 24(3):160-2.
56. Radovanovic D, Jovanovic D, Mihailovic D, et al. Hepatoprotective effects of silymarin in androgenic-anabolic steroid-induced liver damage. Med Pregl (Yugoslavia) 2003; 56(suppl. 1):79-83.
57. Berger J, Kowdley KV. Is silymarin hepatoprotective in alcoholic liver disease? J Clin Gastroenterol 2003; 37(4):278-9.
58. Soto C, Recoba R, Barron H, et al. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comp Biochem Physiol C Toxicol Pharmacol 2003; 136(3):205-12.
59. Lieber CS, Leo MA, Cao Q, et al. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 2003; 37(4):336-9.
60. de Silva HA, Saparamadu PA, Thabrew MI, et al. Liv.52 in alcoholic liver disease: A prospective, controlled trial. J Ethnopharmacol 2003; 84(1):47-50.
61. Atoba MA, Ayoola EA, Ogunseyinde O. Effects of essential phospholipid choline on the course of acute hepatitis-B infection. Trop Gastroenterol 1985; 6:96-9.
62. Canty DJ, Zeisel SH. Lecithin and choline in human health and disease. Nutr Rev 1994; 52:327-339.
63. Hanin I, Ansell GB, eds. Lecithin. Technological, Biological and Therapeutic Aspects. New York and London: Plenum Press, 1987:38-99, 104-125.
64. Jenkins PJ, Portmann BP, Eddleston AL, Williams R. Use of polyunsaturated phosphatidylcholine in HBsAg negative chronic active hepatitis: Results of prospective double-blind controlled trial. Liver 1982; 2:7-81.
65. Kosina F, Budka K, Kolouch Z, et al. Essential cholinephospholipids in the treatment of virus hepatitis. Cas Lek Cesk 1981; 120:957-960.
66. Lieber CS, Leo MA, Cao Q, et al. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 2003; 37(4):336-9.
67. Visco G. Polyunsaturated phosphatidylcholine in association with vitamin B complex in the treatment of acute viral hepatitis B results of a randomized double-blind clinical study. Clin Ter 1985; 114:183-188.
68. Aleynik SI, Leo MA, Ma X, Aleynik MK, Lieber CS. Polyenylphosphatidylcholine protects against alcoholic cirrhosis in the baboon and carbon tetrachloride-induced cirrhosis in rats. J Hepatol 1997; 27(3):554-61.
69. Canty DJ, Zeisel SH. Lecithin and choline in human health and disease. Nutr Rev 1994; 52:327-339.
70. Navder KP, Baraona E, Lieber CS. Polyenylphosphatidylcholine attenuates alcohol-induced fatty liver and hyperlipemia in rats. J Nutr 1997; 127(9):1800-6.
71. Miyazaki M, Bai L, Namba M. Extending effects of phospholipids, cholesterol, and ethanolamines on survival of adult rat hepatocytes in serum-free primary culture. Res Exp Med (Berl) 1991; 191(2):77-83.